Trial Profile
A Randomized Controlled Study of Extracorporeal Photopheresis (ECP) Therapy With UVADEX for the Treatment of Patients With Moderate to Severe Chronic Graft-versus-Host Disease (cGvHD)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 31 Oct 2019
Price :
$35
*
At a glance
- Drugs Methoxsalen (Primary) ; Ciclosporin; Corticosteroids; Prednisone; Tacrolimus
- Indications Graft-versus-host disease
- Focus Therapeutic Use
- Sponsors Mallinckrodt Inc.; Therakos
- 12 Dec 2017 Results assessing safety and efficacy presented at the 59th Annual Meeting and Exposition of the American Society of Hematology
- 19 Feb 2012 New source identified and integrated (Vanderbilt-Ingram Cancer Center; VICCBMT1129).
- 28 Jun 2011 New trial record